Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression

Health Economics

Volumn 17, Issue 11, 2008, Pages 1277-1294

  Zaric, Gregory S ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Markov model; Net benefits; Optimization; Pricing

Indexed keywords

DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG MANUFACTURE; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; MATHEMATICAL ANALYSIS; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROBABILITY; PROFIT; PROSPECTIVE PAYMENT; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; COST BENEFIT ANALYSIS; DRUG INDUSTRY; ECONOMICS; FEE; HUMAN; PHARMACOECONOMICS; RARE DISEASE; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; FEES, PHARMACEUTICAL; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 58749089691     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1332     Document Type: Article

References (16)

1. Adams RA. 1986. Single Variable Calculus. Addison-Wesley: Don Mills, Ontario.
2. Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR. 2006. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Annals of International Medicines 144: 397-406.
3. Campbell JJ. 2005. Understanding Pharma. A Primer on How Pharmaceutical Companies Really Work. Pharmaceutical Institute: Raleigh, NC.
4. Chang RW, Pellisier JM, Hazen GB. 1996. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. Journal of the American Medical Association 275: 858-865.
5. Claxton K. 2007. OFT, VBP: QED? Health Economics 16: 545-558.
6. Coyle D, Buxton MJ, O'Brien BJ. 2003. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Economics 12: 421-427.
7. Devlin N, Parkin D. 2004. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 13: 437-452.
8. Kuntz KM, Goldie SJ. 2002. Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias. Medical Decision Making 22: 218-227.
9. Laking G, Lord J, Fischer A. 2006. The economics of diagnosis. Health Economics 15: 1109-1120.
10. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL. 1995. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New England Journal of Medicine 332: 1418-1424.
11. Mas-Colell A, Whinston MD, Green JR. 1995. Microeconomic Theory. Oxford University Press: New York.
12. Schaafmsa J. 2005. The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis. Pharmacoeconomics 23: 121-132.
13. Sculpher M, Gafni A. 2001. Recognizing diversity in public preferences: the use of preference sub-groups in cost effectiveness analysis. Health Economics 10: 317-324.
14. Tambour M, Zethraeus N, Johannesson M. 1998. A note on confidence intervals in cost effectiveness analysis. International Journal of Technology Assessment in Health Care 14: 467-471.
15. Taylor HM, Karlin S. 1994. An Introduction to Stochastic Modeling (revised edn). Academic Press: San Diego.
16. Zaric GS. 2003. The impact of ignoring population heterogeneity when Markov models are used in cost effectiveness analysis. Medical Decision Making 23: 379-396.